Sign In
Buy CTSO
$0.489
+0.0090 (+1.88%)
At Close: Jun 03, 2026
CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients
07:08am, Wednesday, 25'th Nov 2020
MONMOUTH JUNCTION, N.J., Nov. 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to tre
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2020 Results - Earnings Call Transcript
10:28pm, Wednesday, 04'th Nov 2020
Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2020 Results - Earnings Call Transcript
Cytosorbents Corp (NASDAQ:CTSO) Shares Acquired by Two Sigma Advisers LP
07:10am, Sunday, 04'th Oct 2020
Two Sigma Advisers LP lifted its position in shares of Cytosorbents Corp (NASDAQ:CTSO) by 24.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Comm
CytoSorbents Corporation (NASDAQ: CTSO) has entered into separate agreements with InvoSurg Inc. and Surgical Partners to commercialize CytoSorb® under its FDA Emergency Use Authorization (EUA) in adu
CTSO: 2Q20 Results Illustrate Surging Demand For CytoSorb
01:05pm, Thursday, 06'th Aug 2020
By M. Marin NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Milestone: more than 100,000 CytoSorb cartridges delivered globally Cytosorbents (NASDAQ:CTSO) reported 2Q20 revenue of $9.8 million this wee
Cytosorbents Corp (CTSO) Q2 2020 Earnings Call Transcript
01:01pm, Wednesday, 05'th Aug 2020
Joining me today are Dr. Phillip Chan, Chief Executive Officer; Vincent Capponi, Chief Operating Officer; Kathleen Bloch, Chief Financial Officer; Dr. Efthymios Deliargyris, Chief Medical Officer; Dr.
Recap: CytoSorbents Q2 Earnings
09:18pm, Tuesday, 04'th Aug 2020
Shares of CytoSorbents (NASDAQ:CTSO) fell 2.15% in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 27.27% year over year to ($0.08), which were in
CytoSorbents Reports Record Second Quarter 2020 Financial Results
08:15pm, Tuesday, 04'th Aug 2020
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery pati
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
Earnings Outlook for CytoSorbents
04:47pm, Monday, 03'rd Aug 2020
CytoSorbents (NASDAQ: CTSO) releases its next round of earnings this Tuesday, August 04. Here's Benzinga's essential guide to CytoSorbents's Q2 earnings report.Earnings and Revenue CytoSorbents's EPS
CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date
11:00am, Monday, 03'rd Aug 2020
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery pati
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the Assistant Secretary of Defense for Health Affairs, endorsed b
CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically
CytoSorbents to Report Q2 2020 Operating and Financial Results
10:00am, Tuesday, 28'th Jul 2020
CytoSorbents Corporation (CTSO), CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in crit
